Pharmacological protection of the ischemic myocardium by derivatives of 3-(2,2,2-trimethylhydrazinium) propionate and evaluation of their antioxidant activity
DOI:
https://doi.org/10.18413/2500-235X-2015-1-4-25-31Abstract
The paper presents results of a study of antioxidant (in vitro) and anti-ischemic effect of a number derivatives of 3-(2,2,2-trimethylhydrazinium) propionate. It was revealed that among other compounds 5-hydroxynicotinate of 3-(2,2,2-trimethylhydrazinium) propionate had the most pronounced antioxidant activity. The effect of 3-(2,2,2-trimethylhydrazinium) propionate and its derivatives on the necrotized area of the myocardium of the left ventricle in the course of simulation of myocardial infarction with coronary occlusion in rabbits showed that pharmacological preconditioning by 3-(2,2,2-trimethylhydrazinium) propionate and its derivatives could be considered as prevention of a syndrome of ischemia/reperfusion injury in case of myocardial infarction. Thus it was demonstrated that both 3-(2,2,2-trimethylhydrazinium) propionate (40 mg/kg) and its derivatives, namely nicotinate (84.1 mg/kg), 5-bromonicotinate (105.5 mg/kg), 5-hydroxynicotinate (88.5 mg/kg) and glycine (71.0 mg/kg) had anti-ischemic activity expressed in effective decrease of the area of necrotized infarction and reduction of the level of Tn I in the blood plasma as compared to the reference substance, i.e. Mildronate®.
Keywords:
3-(2,2,2-trimethylhydrazinium) propionate, ischemia/reperfusion, antioxidant activity, preconditioningReferences
G. A. Akimov, V. Yu Polumiskova. Prospects of application of myocardial cytoprotectors in cardiology practice [Electronic resource]. Terra medica. Cardiology. No. 4. (2005): P 21-23. URL: http://www.terramedica.spb.ru/4_2005/akimov.htm.
L. M. Danilenko, O. V. Kharitonova, M. V. Pokrovsky. Endotheliazation Mildronate and its derivatives in modeling L-NAME induced nitrogen oxide. Scientific statement BSU. Ser. Medicine. Pharmacy. № 16, vol. 22/2 (2011): P. 58-62.
L. M. Danilenko, M. V. Pokrovsky O. V. Kharitonova Effects of inducible, endothelial NO synthase ATP-dependent potassium channels in effects of 3-(2,2,2-trimethylhydrazine) propionate and distant preconditioning in the simulation koronarolitikov myocardial infarction. Bulletin of the Volgograd state medical University. Proceedings of the III all-Russian. scientific.-practical. seminar for mol. scientists "Methodol. aspects of experimental. and the clinical. pharmacology", Volgograd, 20-21 Sept. (2011): P. 24-25.
M. V. Korokhin, E. N. Pashin, V. M. Pokrovskii. Study endotelialnogo and coronary action of derivatives of 3-oksipiridina/ // Kuban Scientific medical Bulletin. №4 (2009): P. 104-108.
Lukyanova L. D. New approaches to the creation of antihypoxants of metabolic action. Bulletin of the Russian Academy of medical Sciences. №3 (1999): P. 18-25.
E. B. Manukhina, I. Y. Malyshev, D. A. Pokidishev. Role of free and deposited of nitric oxide in adaptation to hypoxia cardiovascular system. Regional circulation and microcirculation. №3 (2004): Р. 3-11.
Hjalmarson. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?. Basic Res Cardiol. Vol. 95 (2000): P. L41-L45.
Sesti, B.Z. Simkhovich, I. Kalvinsh. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J. Cardiovasc. Pharmacol. № 3. Vol. 47 (2006): P. 493-499.
R.S. Schofield., J.A. Hill Schofield. Role of metabolically active drugs in the management of ischemic heart disease. Am. J. Cardiovasc. Drugs. Vol. 1, № 1. (2001): P. 23-35.
N. Sjakste, A.L. Kleschyov, J.L. Boucher. Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate. Eur. J. Pharmacol. Vol. 495, № 1 (2004). P. 67-73.